IL2 and neoplasm: Seven mice (70%) of the Neuro-IL2/IL12 vaccine group and nine (90%) of the AJ-IL2/IL12 vaccine group remained tumour free for over 3 months, a significant improvement over the control group where 100% of the mice developed tumours and were killed at 12 days post engraftment (P<0.01).